Sector News

Novartis reshuffles its $9B R&D operation

January 27, 2016
Life sciences

Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines.

In tandem with its annual financial results, the company said it promoted former head of development Vas Narasimhan to the newly created position of chief medical officer, tasking him with overseeing the company’s roughly $9 billion drug development operation. In that role, Narasimhan will join the executive committee and work alongside incoming R&D chief Jay Bradner, an award-winning Harvard University oncologist who will take over for Mark Fishman as head of the Novartis Institutes for BioMedical Research in March.

The idea, according to Novartis, is to better coordinate its wide-ranging, disparate development arm by putting one person at the helm, improving “resource allocation, technology and standards across divisions,” the company said. Novartis is also consolidating its medical policy, safety and pharmacovigilance divisions under Narasimhan.

The move is part of an over-arching strategy to make the company more efficient, Novartis said, an effort that includes consolidating manufacturing and shaking up generics to save $1 billion a year starting in 2020. Novartis expects to record restructuring costs of $1.4 billion spread over 5 years.

With those savings, Novartis said it plans to further invest in its R&D division, whose annual budget dipped about 2% in 2015 to $9 billion.

Novartis’ research operation had a big year in 2015, winning approval for a pair of expected blockbusters in the heart failure therapy Entresto and psoriasis treatment Cosentyx, plus picking up the first ever FDA nod for a biosimilar with a version of Amgen’s Neupogen.

By Damian Garde

Source: Fierce Biotech

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach